ClinicalTrials.gg
CompletedNCT05358886Updated Jul 10, 2026

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

A Phase 3 interventional study of BPN14770/ zatolmilast and Placebo in Fragile X Syndrome, sponsored by Tetra Discovery Partners. Completed at 17 sites in United States. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Tetra Discovery Partners (part of Shionogi) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.

Enrollment
11th of 68
171 · median 60
Started
2022
with 6 others
Phase 3
6 of 82
none open now
Registered
68th of 82
by date
Lead sponsor
4 of 82
Tetra Discovery Partners

Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 11th largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2022, is one of 6 in phase 3, and was the 68th registered.

Fragile X Syndrome

115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.

Browse Fragile X Syndrome studies →

Open to participants now

11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Fragile X Syndrome with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome

03

Conditions studied

  • Fragile X Syndrome

Browse trials for

Keywords

  • FXS
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subject aged 18 to 45 years at screening visit.
  2. Subject has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1)mutation (≥200 CGG repetitions).
  3. Subject is able to swallow capsules.
  4. Current treatment with ≤3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for the treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications.
  5. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks prior to screening and must remain stable during the period between screening and the commencement of the study treatment.
  6. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to screening and must remain stable during the period between screening and commencement of the study treatment.
  7. Subjects with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure free for 3 months preceding screening or must be seizure free for 2 years if not currently receiving anti-epileptics.
  8. Behavioral and other non-pharmacological treatments/interventions must be stable for 4 weeks prior to screening and must remain stable during the period between screening and first dose of study treatment and throughout the study. Minor changes in hours or times of therapy that are not considered will not be exclusionary. Changes in therapies provided through a program (eg, due to a vacation) are allowed.
  9. Subject must be willing to practice barrier methods of while on the study if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.
  10. Subject has a parent, legal authorized guardian, or consistent caregiver.
  11. Subject and caregiver are able to attend the clinic regularly and reliably.
  12. If subject is his own legal guardian, he is able to understand and sign to participate in the study.
  13. For subjects who are not their own legal guardian, subject's parent/legally authorized guardian is able to understand and sign an informed consent form for their child to participate in the study.
  14. If subject is not his own legal guardian, subject must provide assent for participation in the study if he has the cognitive ability to do so.

Exclusion criteria

Exclusion Criteria:

  1. Inability to successfully complete the NIH-TCB picture vocabulary and oral reading assessments at screening and baseline. The ability to complete the NIH-TBC oral reading and picture vocabulary subtest at baseline is defined as the ability to complete both subtests, with (1) confirmation from the clinician administering that the test administrations are valid (noted on the administration form) and (2) generation of valid test scores for each test.
  2. History of or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the subject at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study treatment.

    a. Common conditions such as mild hypertension, etc. are allowed per the principal investigator's judgement as long as they are stable and controlled by medical therapy that is constant for at least 4 weeks before randomization.

  3. Renal impairment, defined as serum creatinine > 1.25 × at screening
  4. Hepatic impairment, defined as or AST elevation > 2 × ULN at screening. Note: LFTs may be repeated after 1 week to evaluate return to acceptable limits; if LFTs remain elevated, the subject is ineligible to participate.
  5. abnormalities, in the investigator's judgement, in safety laboratory tests, vital signs, or , as measured during screening.
  6. History of substance abuse within the past year, according to investigator assessment.
  7. Positive COVID-19 test during screening.
  8. Significant hearing or visual impairment that may affect the subject's ability to complete the test procedures.
  9. Concurrent major psychiatric condition (eg, major depressive disorder, schizophrenia, or bipolar disorder) as diagnosed by the investigator. Subjects with the additional diagnosis of autism spectrum disorder or anxiety disorder will be allowed.
  10. Subject has active diseases that would interfere with participation, such as acquired immunodeficiency disorder, , , or tuberculosis.
  11. Subject is planning to commence psychotherapy or cognitive behavior therapy during the period of the study or had begun psychotherapy or cognitive behavior therapy within 4 weeks prior to screening.
  12. Subject is an immediate family member of anyone employed by the sponsor, investigator, or study staff.
  13. Subject has a of less than 18 kg/m2 or greater than 36 kg/m2.
  14. Subject has participated in another clinical trial within the 30 days preceding Screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Active comparator
    Study Drug

    25mg BID BPN14770

    Drug: BPN14770/ zatolmilast

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugBPN14770/ zatolmilast

    Drug page: BPN14770

    25mg BID BPN14770

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. National Institutes of Health Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC)

    National Institutes of Health Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC), which is calculated from the Picture Vocabulary and Oral Reading domains.

    Time frame: 13 Weeks

Secondary outcomes

  1. Numerical rating scale (NRS) scores based on subject-specific behaviors vs baseline

    Numerical rating scale (NRS) scores based on subject-specific behaviors within the domains of Daily Function and Language

    Time frame: 13 Weeks

  2. Caregiver Global Impression of Improvement (CaGI-I)

    Caregiver Global Impression of Improvement (CaGI-I) for the general domains of Daily Function and Language

    Time frame: 13 Weeks

  3. Clinical Global Impression Improvement (CGI-I) for - Investigator

    Clinical Global Impression Improvement (CGI-I) for - Investigator rated the general domains of Daily Function and Language

    Time frame: 13 Weeks

  4. Vineland-3 Adaptive Behavior Scale (Vineland-3)

    Vineland-3 Adaptive Behavior Scale (Vineland-3), using the composite score and domain scores from communication, daily living skills, and socialization

    Time frame: 13 Weeks

  5. Verbal Knowledge test from the Stanford-Binet (ed 5) (SB-5)IQ

    Verbal Knowledge test from the Stanford-Binet (ed 5) (SB-5) IQ assessment

    Time frame: 13 Weeks

  6. NIH-TCB domains of Picture Sequence Memory, Flanker Inhibitory Control and Attention, List Sorting Working Memory, Dimensional Change Card Sort, and Speeded Matching

    NIH-TCB domains of Picture Sequence Memory, Flanker Inhibitory Control and Attention, List Sorting Working Memory, Dimensional Change Card Sort, and Speeded Matching

    Time frame: 13 Weeks

  7. Aberrant Behavior Checklist (ABC) scores

    Aberrant Behavior Checklist (ABC) scores

    Time frame: 13 Weeks

  8. Anxiety, Depression, and Mood Scale (ADAMS) scores

    Anxiety, Depression, and Mood Scale (ADAMS) scores

    Time frame: 13 Weeks

07

Study locations

17 sites
  • Amnova Clinical Research
    Irvine, California 92604, United States
  • Thompson Autism & Neurodevelopment Center - CHOC
    Orange, California 92868, United States
  • UC Davis Health System
    Sacramento, California 95817, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • Icahn School of Medicine at Mount Sinai Hospital
    New York, New York 10029, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Clinic for Special Children
    Strasburg, Pennsylvania 17579, United States
  • Greenwood Genetic Center
    Greenville, South Carolina 29605, United States
  • University of Utah and Primary Childrens Hospital
    Salt Lake City, Utah 84113, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jul 2025, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 3, 2022
StartActual
Nov 1, 2022
Primary completionActual
Jul 18, 2025
CompletionActual
Jul 18, 2025
Results delay requested
Jul 7, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05358886
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Nov 1, 2022
Primary completion
Jul 18, 2025
Completion
Jul 18, 2025
Last update
Jul 10, 2026

Study contacts

Elizabeth Berry-Kravis, MD
principal investigator · Rush Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPN14770

Start the discussion